• 8:30 - 18:00 M-T / 8.30 - 15.00 F


ASC pre-differentiated to osteoblasts in Histobone scaffold (engineered synthetic bone substitute) for the treatment of bone defects caused by pseudoarthrosis, infections, resections, trauma).

Program licensed to:




Regenerative capabilities of cells.

Guided osseous re-modelling process due to scaffold properties.

Excellent integration of newly formed tissue with surrounding tissue.

Adequate revascularisation.

Development stage

Clinical Phase II ongoing Q2 2018 with allogenic product.

Licensing & co-development agreement with Salvat.

2017: 6 patients treated with Bonecure autologous product and medical discharged as bone consolidation has been achieved.

Recruitment of phase II was completed in 2019.

2018-2020: evaluation of the clinical trial with 6 patients treated with allogeneic Bonecure.

More information

Histocell Headquarters

Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900

Histocell Factory

Polígono Sasine. Patakon s/n
48195 Larrabetzu
Bizkaia - Spain

+34 94 656 7900

Our mision

We develop new advanced therapy medicinal products, medical devices and dermocosmetics to improve people's quality of life.

Copyright © Histocell